{"id":"interferon-1b","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Flu-like symptoms"},{"rate":"20-40%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"This cytokine binds to the interferon gamma receptor (IFNGR), leading to the activation of the JAK-STAT signaling pathway, which results in the upregulation of genes involved in immune response and inflammation.","oneSentence":"Interferon γ-1b enhances immune responses by activating macrophages and natural killer cells, and it also has antiviral properties.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:28.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic granulomatous disease (CGD)"},{"name":"Severe, malignant osteopetrosis"}]},"trialDetails":[{"nctId":"NCT06529731","phase":"PHASE2","title":"Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Sawa Ito, MD","startDate":"2024-09-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":45},{"nctId":"NCT02593773","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-12-25","conditions":"Friedreich's Ataxia","enrollment":86},{"nctId":"NCT02415127","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-06","conditions":"Friedreich's Ataxia","enrollment":92},{"nctId":"NCT02797080","phase":"PHASE3","title":"Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-06-28","conditions":"Friedreich's Ataxia","enrollment":38},{"nctId":"NCT02609932","phase":"PHASE1","title":"Effect of IFN-γ on Innate Immune Cells","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-07","conditions":"Chronic Granulomatous Disease","enrollment":20},{"nctId":"NCT00084279","phase":"PHASE2","title":"CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)","status":"COMPLETED","sponsor":"InterMune","startDate":"2004-04","conditions":"Chronic Hepatitis C","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":96,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACTIMMUNE®"],"phase":"phase_3","status":"active","brandName":"interferon γ-1b","genericName":"interferon γ-1b","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon γ-1b enhances immune responses by activating macrophages and natural killer cells, and it also has antiviral properties. Used for Chronic granulomatous disease (CGD), Severe, malignant osteopetrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}